Chunlei Ke

2.6k total citations · 2 hit papers
44 papers, 1.9k citations indexed

About

Chunlei Ke is a scholar working on Oncology, Statistics and Probability and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Chunlei Ke has authored 44 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 20 papers in Statistics and Probability and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Chunlei Ke's work include Bone health and treatments (19 papers), Statistical Methods in Clinical Trials (17 papers) and Health Systems, Economic Evaluations, Quality of Life (9 papers). Chunlei Ke is often cited by papers focused on Bone health and treatments (19 papers), Statistical Methods in Clinical Trials (17 papers) and Health Systems, Economic Evaluations, Quality of Life (9 papers). Chunlei Ke collaborates with scholars based in United States, Canada and Finland. Chunlei Ke's co-authors include Fred Saad, Carsten Goessl, Teuvo L.J. Tammela, Benjamin Z. Leder, Blair Egerdie, Jiří Heráček, Narciso Hernández Toriz, Robert Feldman, Matthew Smith and Amy Kupic and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Journal of the American Statistical Association.

In The Last Decade

Chunlei Ke

43 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

2009 786 citations Matthew Smith, Blair Egerdie et al. New England Journal of Medicine profile →
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

2012 420 citations Allan Lipton, Karim Fizazi et al. European Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chunlei Ke United States	13	1.2k	592	546	361	340	44	1.9k
Ker‐Ai Lee Canada	22	973 0.8×	550 0.9×	184 0.3×	512 1.4×	219 0.6×	54	2.4k
Erhard Quebe‐Fehling Switzerland	15	1.2k 1.0×	393 0.7×	212 0.4×	250 0.7×	228 0.7×	42	1.9k
Kan Li United States	20	743 0.6×	344 0.6×	56 0.1×	90 0.2×	180 0.5×	60	1.8k
Philip J. Saylor United States	25	1.0k 0.9×	1.2k 2.0×	145 0.3×	326 0.9×	492 1.4×	82	2.5k
Kristel Vandormael United States	14	1.6k 1.4×	981 1.7×	667 1.2×	81 0.2×	297 0.9×	20	2.4k
M. Budde Switzerland	12	633 0.5×	241 0.4×	127 0.2×	238 0.7×	108 0.3×	27	1.4k
Uma Kher United States	18	898 0.8×	565 1.0×	420 0.8×	43 0.1×	275 0.8×	36	2.1k
Jacques Planas Spain	22	330 0.3×	1.2k 2.0×	97 0.2×	120 0.3×	330 1.0×	137	1.6k
J. N. Ingle United States	18	1.4k 1.2×	501 0.8×	68 0.1×	362 1.0×	376 1.1×	43	2.4k
Daniel A. Nikcevich United States	24	1.3k 1.1×	449 0.8×	39 0.1×	142 0.4×	437 1.3×	72	2.3k

Countries citing papers authored by Chunlei Ke

Since Specialization

Citations

This map shows the geographic impact of Chunlei Ke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chunlei Ke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chunlei Ke more than expected).

Fields of papers citing papers by Chunlei Ke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chunlei Ke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chunlei Ke. The network helps show where Chunlei Ke may publish in the future.

Co-authorship network of co-authors of Chunlei Ke

This figure shows the co-authorship network connecting the top 25 collaborators of Chunlei Ke. A scholar is included among the top collaborators of Chunlei Ke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chunlei Ke. Chunlei Ke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dixon, Bradley P., Larry A. Greenbaum, Liwei Huang, et al.. (2023). Clinical Safety and Efficacy of Pegcetacoplan in a Phase 2 Study of Patients with C3 Glomerulopathy and Other Complement-Mediated Glomerular Diseases. Kidney International Reports. 8(11). 2284–2293. 33 indexed citations

Snapinn, Steven, Qi Jiang, & Chunlei Ke. (2022). Treatment effect measures under nonproportional hazards. Pharmaceutical Statistics. 22(1). 181–193. 7 indexed citations

Elliott, Colm, Douglas L. Arnold, Chunlei Ke, et al.. (2020). Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions. American Journal of Neuroradiology. 41(9). 1584–1591. 33 indexed citations

Jiang, Qing, Donglin Zeng, Chunlei Ke, et al.. (2020). A Counterfactual P -Value Approach for Benefit-Risk Assessment in Clinical Trials. UNC Libraries.

Psioda, Matthew A., et al.. (2019). Bayesian adaptive basket trial design using model averaging. Biostatistics. 22(1). 19–34. 36 indexed citations

Diao, Guoqing, Jun Dong, Donglin Zeng, et al.. (2018). Biomarker threshold adaptive designs for survival endpoints. Journal of Biopharmaceutical Statistics. 28(6). 1038–1054. 10 indexed citations

Ke, Chunlei, Jianming Wang, Charlie Zhang, Qi Jiang, & Steven Snapinn. (2017). On Errors in Stratified Randomization. Statistics in Biopharmaceutical Research. 9(2). 225–233. 4 indexed citations

Jiang, Qi, Christy Chuang‐Stein, Cyrus R. Mehta, et al.. (2017). Statistical Considerations for Cardiovascular Outcome Trials in Patients with Type 2 Diabetes Mellitus. Statistics in Biopharmaceutical Research. 9(4). 347–360. 3 indexed citations

Ma, Haijun, Chunlei Ke, Qi Jiang, & Steven Snapinn. (2015). Statistical Considerations on the Evaluation of Imbalances of Adverse Events in Randomized Clinical Trials. Therapeutic Innovation & Regulatory Science. 49(6). 957–965. 11 indexed citations

10.

Zhou, Ying, Chunlei Ke, Qi Jiang, Seta Shahin, & Steven Snapinn. (2015). Choosing Appropriate Metrics to Evaluate Adverse Events in Safety Evaluation. Therapeutic Innovation & Regulatory Science. 49(3). 398–404. 12 indexed citations

11.

Lipton, Allan, Karim Fizazi, Alison Stopeck, et al.. (2012). Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. European Journal of Cancer. 48(16). 3082–3092. 420 indexed citations breakdown →

12.

Ke, Chunlei, Beiying Ding, Qi Jiang, & Steven Snapinn. (2012). The issue of multiplicity in noninferiority studies. Clinical Trials. 9(6). 730–735. 3 indexed citations

13.

Egerdie, R. Blair, Fred Saad, Mitchell R. Smith, et al.. (2012). Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. Prostate Cancer and Prostatic Diseases. 15(3). 308–312. 15 indexed citations

14.

Stopeck, Alison, Gary Richardson, Salvatore Siena, et al.. (2012). AOS13 Denosumab versus zoledronic acid for the prevention of skeletal-related events in patients with bone metastases secondary to solid tumours: An integrated analysis of three phase 3 studies. European Journal of Cancer. 48. S8–S8. 1 indexed citations

15.

Coleman, Robert E., Carlos H. Barrios, R. Bell, et al.. (2012). Denosumab Versus Placebo as Adjuvant Treatment for Women With Early-Stage Breast Cancer at High Risk of Disease Recurrence (D-CARE): An in Progress, Phase 3 Clinical Trial. Annals of Oncology. 23. ix115–ix115. 2 indexed citations

16.

Miller, Kurt, Karim Fizazi, Matthew R. Smith, et al.. (2011). 648 BENEFIT OF DENOSUMAB THERAPY IN PATIENTS WITH BONE METASTASES FROM CASTRATE RESISTANT PROSTATE CANCER: A NUMBER-NEEDED-TO-TREAT (NNT) ANALYSIS. The Journal of Urology. 185(4S). 6 indexed citations

17.

Smith, Matthew, Blair Egerdie, Narciso Hernández Toriz, et al.. (2009). Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer. New England Journal of Medicine. 361(8). 745–755. 786 indexed citations breakdown →

18.

Wang, Yuedong & Chunlei Ke. (2009). Smoothing Spline Semiparametric Nonlinear Regression Models. Journal of Computational and Graphical Statistics. 18(1). 165–183. 8 indexed citations

19.

Smith, Matthew Ryan, Blair Egerdie, Robert Feldman, et al.. (2009). 846 A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF DENOSUMAB IN MEN RECEIVING ANDROGEN DEPRIVATION THERAPY FOR NON-METASTATIC PROSTATE CANCER. European Urology Supplements. 8(4). 332–332. 2 indexed citations

20.

Wang, Yuedong, Chunlei Ke, & Morton B. Brown. (2003). Shape‐Invariant Modeling of Circadian Rhythms with Random Effects and Smoothing Spline ANOVA Decompositions. Biometrics. 59(4). 804–812. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact